These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 33762818)

  • 1. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.
    Yang Y; Cui X; Wei H; Guo C; Zhang Y
    Drug Des Devel Ther; 2021; 15():1213-1223. PubMed ID: 33762818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
    Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
    Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2.
    Shahid M; Shahzad-Ul-Hussan S
    J Struct Biol; 2021 Mar; 213(1):107690. PubMed ID: 33383190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valinomycin as a potential antiviral agent against coronaviruses: A review.
    Zhang D; Ma Z; Chen H; Lu Y; Chen X
    Biomed J; 2020 Oct; 43(5):414-423. PubMed ID: 33012699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis of SARS-CoV-2- and SARS-CoV-Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.
    Sivaraman H; Er SY; Choong YK; Gavor E; Sivaraman J
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():465-493. PubMed ID: 32574109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
    Idrees M; Khan S; Memon NH; Zhang Z
    Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target.
    Wang Y; Anirudhan V; Du R; Cui Q; Rong L
    J Med Virol; 2021 Jan; 93(1):300-310. PubMed ID: 32633831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2: Targeted managements and vaccine development.
    Bakhiet M; Taurin S
    Cytokine Growth Factor Rev; 2021 Apr; 58():16-29. PubMed ID: 33293238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.
    Marian AJ
    Cardiovasc Pathol; 2021; 50():107278. PubMed ID: 32889088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.